Europe's Biotech Appeal for Clinical Research

🚨 In recent years, 66 out of 67 European biotech companies chose to go public on markets outside the EU. That single number says a lot about Europe’s life sciences paradox: world-class research, yet most European biotech companies still look beyond Europe when it’s time to grow. BioVox’s latest article dives deeper into this challenge, highlighting why access to funding, stronger growth pathways and better conditions for scaling remain essential if Europe wants to keep innovation here, not just create it. At Biovia, this is exactly where we focus our efforts. Supporting the translation of science into real-world impact — and improving access to funding and scaling opportunities — remains a core priority for us and our ecosystem. The article also points to structural barriers across Europe’s capital markets and regulatory landscape, which continue to shape where and how biotech companies choose to list and scale. ➡️ Get the full breakdown: https://lnkd.in/ed6EUU4n Platforms that bring together research leaders, investors, and policymakers are becoming increasingly important. That's why we look forward to continuing this conversation at Knowledge for Growth, where these challenges—and solutions—will be front and center. “Europe’s life sciences industry is strong, but its future will depend on how well we connect our strengths across borders and sectors.” – Ann Van Gysel 📆 03 & 04 June | 📍 Antwerp 🎫 See you at #KFG2026: https://lnkd.in/gsE4P46

🔬 Speaker Spotlight | Investigator-Initiated Trials Conference 2026 🇵🇹 Funding remains one of the biggest unlocks — and bottlenecks — in investigator-initiated trials across Europe. That’s why we’re bringing the conversation to the forefront with Dr. Maria Jose Ruiz Alvarez, Istituto Superiore di Sanità who will be sharing her expert perspective on: 🎤 “Investigator-Initiated Clinical Research Funding in Europe: What Works and What’s Missing” Across Europe, IITs are evolving — but funding structures haven’t always kept pace. 💡 Where are the gaps? 💡 What models are actually working? 💡 And how do we ensure investigator-led research reaches its full potential? Expect a session grounded in real-world experience, tackling: ✔️ The realities of funding access across European markets ✔️ Barriers limiting investigator-led innovation ✔️ Opportunities to build more sustainable, scalable funding pathways ✔️ The role of collaboration in unlocking high-impact research This isn’t theory — it’s a practical look at how funding shapes the future of clinical research.. 📍 Lisbon, Portugal 📅 June 18th-19th 🏨 EPIC SANA Marquês 🎟️ Registration is now open — join clinical research leaders advancing the future of investigator-led innovation 📧 info@twoknctmedia.com 🌐 www.twoknctmedia.com If you’re involved in IITs, clinical development, or research strategy — this is a conversation you need to be part of. 👉 Are we funding research… or enabling impact? #InvestigatorInitiatedTrials #IIT #ClinicalResearch #ClinicalTrials #MedicalResearch #HealthcareInnovation #Biotech #Pharma #Europe #LifeSciences

Europe leads in advanced therapy research, but to stay competitive globally we must strengthen clinical trials, increase visibility of European capabilities, and turn scientific excellence into scalable innovation and investment. Read more about it in the interview with Dr. Montse Daban Marín , President of the Council of European BioRegions - CEBR and the project owner of PRECISEU

Ingeborg ter Laak, Member of the European Parliament, visited TNO today in Leiden. The occasion: the European Biotech Act and an urgent European challenge. Europe has the science. But it falls short in translating this into clinical applications and market introduction. That is exactly what the European Biotech Act aims to address. We discussed the role of Research & Technology Organisations in Europe’s competitiveness, and what FP10 and the European Competitiveness Fund could concretely mean for accelerating this process. At Peregrion, it became clear how TNO contributes. Techniques such as microtracing and metabolite analysis make the clinical development of new medicines faster and more efficient. This is the translational strength Europe needs. Many thanks to everyone involved for the open and valuable exchange on how we can jointly strengthen the European biotech ecosystem. Robert Kleemann | Christine Balch | David van Hees | Martin Kirch | Wouter Bulten | Erik Drop | Helene Meijer | Rijk van Walsem | Wietske Veltman | Steven Erpelinck | Esther van Duijn

Heading to #SwissBiotechDay 2026? So are we ✈️ Lithuania has become one of Europe's fastest-growing life sciences hubs, trusted by global leaders like Thermo Fisher Scientific, Hollister, and Dräger. Why? Well, much like the Swiss Army knife, it packs everything you need into one place: 👩🔬 Access to highly educated, tech-savvy talent - with up to 3x lower labour costs than elsewhere in Europe 🚀 Fast-track setup and targeted government incentives - including a triple R&D tax deduction and up to 40% capital investment support 🩺 EHDS-ready health data with 95%+ population coverage - built for real-world evidence and clinical validation 📈 Biomanufacturing firms report 25–30% higher profitability compared to the rest of their group Let's talk more about it at the conference. Reach out to Greta Zajančauskaitė and Kornelija Bakutyte to schedule a meet-up. And see you in Basel! 🏞️ 👤 Swiss Biotech Association

European biotech has the science and the clinical capability to run complex trials at scale. The question in 2026 is whether the ecosystem - capital, regulatory frameworks, exit pathways, and the people within it is catching up fast enough.   Kamil Sitarz, PhD, MBA, our COO, will be sharing his perspective on exactly that at OCT Europe 2026 in Barcelona across two panels.   📆 May 6, 2:00 PM CET 🎙️ The Biotech Landscape in Europe 2026: Growth, Shifts & Strategic Outlook ✔️ Where capital is actually flowing — and what investors want to see in 2026 ✔️ Talent gaps and how European biotechs compete for the right people ✔️ Regional shifts: why CEE clinical execution capability is an underused argument in investor conversations ✔️ How political and economic changes are reshaping strategic decisions across the continent   📆 May 7, 2:45 PM CET 🎙️ Future of Clinical Trial Professionals: Technology & Workforce Transformation ✔️ How AI and automation are reshaping roles across clinical trial functions ✔️ Ensuring human expertise drives technology — not the other way around   As COO of Ryvu Therapeutics, Kamil oversees several oncology programs running across Europe. These aren’t abstract questions.   If you’re attending OCT Europe, Kamil is happy to talk. 🙌   #OCTEurope2026 #ClinicalTrials #ClinicalOperations #Biotech #EuropeanBiotech #RyvuTx

Swiss Biotech Day opened with a big showing by Australian companies. Western Australian Company Linear Clinical Research proudly showcasing WA clinical trials capability.   Australian Trade and Investment Commission (Austrade) Invest and Trade Western Australia Swiss Biotech Association

On behalf of BioCentury and Informa, many thanks to all who joined the 26th BioEquity Europe in Prague last week and a special thanks to all our sponsors and speakers. A few takeaways: ✤ Innovation can happen anywhere: This was the first time BioEquity took place in Central Europe and I learned a lot about opportunities emerging in the region, including clinical trials. It was also a history lesson for those who don't know the story behind Gilead Sciences and the partnership between John Martin and Prof. Holy of IOCB Tech. At the invitation of regional host chair Prague.bio, BioCentury attended a showing of a local play called the "Elegance of the Molecule" that tells this story -- highly recommended. ✤ Europe at a crossroads: There's a recognition by many that Europe is at a crossroads given uncertainty in the U.S. market and the rise of China biotech. Many are hopeful this will galvanize action: From pension funds and growth capital to reimbursement of innovation. One to watch. ✤ China: It continues to dominate the discussion. Regardless of your position on China, there is a recognition now that you cannot sit still. You must generate faster clinical data to de-risk assets for partners and investors. Some will find partners in China or Australia, some will look for solutions closer to home. There was much discussion about oncology clinical trials in Spain, e.g. ✤ MFN: The U.S. MFN policy is keeping a lot of European CEOs and investors up at night. At the same time, there is also a whisper, which is growing louder: What if this becomes a China story too? If Europe has to increase spend on defense and energy, what if it cannot also increase spend on innovative drugs? What if Europe instead cuts deals with China biopharma for more affordable innovation? One to watch. If you missed this year's event, join us next year in Copenhagen for the 27th BioEquity Europe with a regional host committee chaired by Novo Holdings and Lundbeckfonden / Lundbeck Foundation. Super early bird registration is now open. I hope to see you there! #biotech #venturecapital #BioEquityEurope

The aftermath of MFN, and the interplay between Europe and China+ is one to definitely watch. Forces on both sides. From a political point of view, European regulators could be wary of creating additional dependency points with China and have a knee jerk reaction to the idea of partnering… From a population needs view point, collaboration East to West, and West to East, make a lot of sense, in a macro environment where the idea of spending significantly more on innovation does not appear realistic given other pressing priorities for all major European governments. Could we see, in the next decade, the emergence of an affordable innovation market, reaching billions of patients? Next to the premium innovation market largely embodied by the US. #innovation #patients

As Australia’s largest CRO, Novotech is proud to join the Australian delegation in Boston on May 14. Steve Roan, Associate Business Development Director at Novotech, will discuss the benefits of Australia for both healthy volunteer and patient studies, along with strategies to accelerate timelines and support successful study outcomes. https://lnkd.in/gu97gnAd